DP
TARS icon

Diadema Partners’s Tarsus Pharmaceuticals TARS Stock Holding History

Diadema Partners’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-25,942
Closed -$1.82M – 194
2026
Q1 		$1.82M Buy
+25,942
New +$1.81M 0.31% 66
2025
Q1 		– Sell
-60,000
Closed -$3.32M – 150
2024
Q4 		$3.32M Buy
+60,000
New +$2.73M 1.43% 23

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Diadema Partners's TARS Position: Q2 2026 in Review

Diadema Partners sold out of Tarsus Pharmaceuticals (TARS) in Q2 2026, closing a stake of 25,942 shares — an estimated $1.82M sold.

Diadema Partners first reported a position in TARS in Q4 2024 and held it in 2 quarters. The position peaked at $3.32M in Q4 2024. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Diadema Partners reported no remaining Tarsus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Diadema Partners sold 25,942 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $1.82M.
  • Diadema Partners first reported a position in Tarsus Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Diadema Partners's Tarsus Pharmaceuticals position peaked at $3.32M in Q4 2024.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.